Dr. Prasad’s Return to FDA: Impact on Biopharma & mRNA Therapies
Dr. Vinay Prasad's return to CBER raises concerns about mRNA therapies and FDA approvals based on surrogate endpoints. Increased scrutiny expected for vaccines and gene therapies. Investors and vaccine programs at risk.